Lipid nanoparticles capable of simultaneously delivering antigens to cancer and dendritic cells, and anticancer composition containing same
The dual-targeting mRNA vaccine addresses antigen deficiency in tumors and dendritic cells by using DEC-205 antibodies to enhance antigen expression and delivery, maximizing CD8+ T cell responses and immune efficacy.
Patent Information
- Application Number
- PCT/KR2026/096883
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-12
- Filing Date
- 2026-05-12
- Publication Date
- 2026-11-19
AI Technical Summary
Existing mRNA vaccines face limitations in antigen expression within tumors, non-specific liver accumulation, and impaired dendritic cell function in the tumor microenvironment, leading to reduced CD8+ T cell responses and immune evasion by cancer cells.
A dual-targeting mRNA vaccine using DEC-205 antibodies to simultaneously express antigens in both dendritic cells and tumor cells, enhancing antigen presentation and targeting strategy to minimize liver accumulation.
The vaccine induces potent CD8+ T cell responses by optimizing antigen expression in both DCs and tumor cells, improving selective delivery to tumors and lymph nodes, and promoting long-term immune memory.
Smart Images

Figure KR2026096883_19112026_PF_FP_ABST
Abstract
Description
Lipid nanoparticles capable of simultaneously delivering antigens to cancer and dendritic cells and anticancer compositions containing the same
[0001] The present invention relates to lipid nanoparticles (LNPs) capable of simultaneously delivering antigens to cancer cells and dendritic cells, and to an anticancer composition containing the same. Specifically, it enables the simultaneous expression of antigens in dendritic cells and tumor cells through a dual-targeting mRNA vaccine targeting DEC-205, thereby resolving the problem of antigen loss within the tumor, and CD8 + This invention relates to lipid nanoparticles capable of maximizing T cell response and anticancer compositions containing the same.
[0002]
[0003] As part of their immune evasion strategies, cancer cells reduce MHC-I expression or decrease the expression of tumor-specific antigens recognizable by immune cells, thereby reducing CD8 + It evades attacks by T cells. This antigen loss phenomenon is a major obstacle to cancer treatment and reduces the effectiveness of existing immunotherapies and vaccines.
[0004] Furthermore, dendritic cells (DCs) responsible for antigen presentation also receive inhibitory signals within the tumor microenvironment, leading to functional impairment, and this is CD8 + It is a major cause of inhibition of T cell activation. DCs play a role in processing externally introduced antigens and presenting them to T cells via MHC-I and MHC-II, but if DC maturation is inhibited in the tumor microenvironment, CD8 + T cell response is reduced, and immune evasion is further strengthened.
[0005] Currently, LNP-based mRNA vaccines primarily utilize a method of delivering antigens by targeting DCs. However, even if antigens are effectively presented to DCs, if antigen expression within tumor cells is insufficient, CD8 +T cell antigen recognition and immune responses may be weakened. Existing mRNA vaccine technologies lack strategies to increase antigen expression within tumors, and if only DCs are targeted, CD8 + It is highly likely that T cell responses will be induced only to a limited extent.
[0006] Furthermore, most currently used LNP-based vaccines have limitations due to high non-specific accumulation in the liver, resulting in low selective delivery efficiency to tumors and lymph nodes. If LNP is preferentially cleared from the liver, antigen expression in tumors or immune organs is restricted, which can lead to a problem of reduced concentration of the immune response.
[0007] To address these issues, technologies are being researched to directly target DCs or tumor cells by modifying the surface of LNPs with specific antibodies. However, existing DC-targeting vaccine technologies have the following limitations.
[0008] First, targeting DCs alone does not resolve the problem of insufficient antigen expression within tumors. Tumor cells induce immune evasion by reducing antigen expression; however, existing vaccine technologies focus on enhancing the antigen presentation function of DCs, so if antigens are not sufficiently expressed in tumor cells, CD8 + T cell responses may be induced to a limited extent.
[0009] Secondly, in a tumor microenvironment where the antigen-presenting function of DCs is impaired, the efficacy of existing mRNA vaccines is likely to decrease. If DCs fail to present sufficient antigens, CD8 + T cell responses are weakened, which can result in further promoting immune evasion.
[0010] Third, existing LNP-based vaccines exhibit high non-specific accumulation in the liver, which limits selective delivery to tumors and lymph nodes. When antigens are expressed non-specifically in the liver, the immune response is dispersed, and the direct immune effect against tumors is reduced.
[0011] To solve these problems, the present invention provides a technology that maximizes the anti-cancer immune response by developing a dual-targeting mRNA vaccine targeting DEC-205 and expressing the antigen in both DCs and tumor cells, thereby simultaneously increasing antigen expression in DCs and tumor cells, and CD8 + It enables T cell responses to be induced more potently. DEC-205 (CD205) is a C-type lectin receptor expressed in dendritic cells (DCs) and some cancer cells, responsible for antigen capture and delivery.
[0012] The present invention overcomes the limitations of existing mRNA vaccines' sole targeting of DCs and resolves the problem of antigen deficiency within tumors, thereby inducing a more powerful anti-cancer immune response.
[0013]
[0014] The objective of the present invention is to develop a dual-targeting mRNA vaccine targeting DEC-205 and provide a technology that maximizes the anti-cancer immune response by simultaneously expressing antigens in DCs and tumor cells.
[0015] As part of their immune evasion strategies, cancer cells reduce MHC-I expression or decrease the expression of tumor-specific antigens recognizable by immune cells, thereby reducing CD8 + They evade T cell attacks. Furthermore, in the tumor microenvironment, the antigen presentation function of DCs is impaired, which is CD8 + It is a major cause of inhibiting T cell activation. To solve this problem, the present invention developed a technology to optimize antigen expression of mRNA vaccines by introducing the DEC-205 antibody onto the surface of LNP and simultaneously targeting DCs and tumor cells.
[0016] Through this technology, by increasing antigen expression within cancer cells to suppress immune evasion strategies and enhancing the antigen presentation function of DCs, CD8 +It can maximize T cell responses. Unlike conventional vaccines that target DCs alone, the vaccine platform of the present invention is designed to induce a more potent anti-cancer immune response by directly expressing antigens not only in DCs but also in tumor cells.
[0017] Furthermore, the DEC-205 dual-targeting vaccine resolves the problem of non-specific accumulation in the liver associated with existing mRNA vaccines and can maximize selective delivery to tumors and lymph nodes. This enhances the concentration of the immune response and optimizes the efficacy of anticancer treatment.
[0018] The present invention can contribute to overcoming the limitations of existing anticancer vaccines and establishing next-generation cancer immunotherapy strategies through combination with immunotherapies and antibody-based therapies.
[0019]
[0020] The present invention provides a pharmaceutical composition for the prevention or treatment of cancer in which a DEC-205 receptor is expressed on the surface of cancer cells, comprising a 'DEC-205 bound lipid nanoparticle' having an antibody or antibody fragment capable of binding to both a DEC-205 receptor expressed on the surface of dendritic cells and a DEC-205 receptor expressed on the surface of cancer cells' bound to the lipid nanoparticle, and having mRNA loaded therein.
[0021] In the pharmaceutical composition of the present invention, the 'antibody or antibody fragment thereof capable of binding to both the DEC-205 receptor expressed on the surface of dendritic cells and the DEC-205 receptor expressed on the surface of cancer cells' can preferably be bound to lipid nanoparticles through chemical bonding.
[0022] At this time, the chemical bond is, for example, a maleimide-thiol reaction in which a maleimide functional group is introduced into the lipid of a lipid nanoparticle, and a chemical reaction is induced between the maleimide functional group and the thiol functional group of an antibody to form a chemical bond; an amine-carboxyl reaction in which a chemical bond is formed between a carboxyl group (-COOH) present in the lipid of the lipid nanoparticle and an amine group (-NH2) of the antibody; or a click chemistry (CuAAC, SPAAC) reaction in which an azide (-N₃) or alkyne (-C≡C) functional group is introduced into the lipid of the lipid nanoparticle and a click-reactive functional group is introduced into the antibody, and a chemical bond is formed through a click reaction between them. It can be formed by any one of the following chemical reactions: a hydrazine or oxime bonding reaction in which an aldehyde functional group is introduced into the lipid of the lipid nanoparticle and a hydrazine (-NH-NH₂) or oxime (-C=NOH) functional group is introduced into the antibody, and then a chemical reaction between them is induced to form a chemical bond; and a Staudinger ligation reaction in which a phosphine functional group is introduced into the lipid of the lipid nanoparticle and an azide (N₃) functional group is introduced into the antibody, and then a chemical reaction between them is induced to form a chemical bond.
[0023] In the pharmaceutical composition of the present invention, the 'antibody or antibody fragment thereof capable of binding to both the DEC-205 receptor expressed on the surface of a dendritic cell and the DEC-205 receptor expressed on the surface of a cancer cell' may, for example, be formed by binding the 'antibody or antibody fragment thereof capable of binding to both the DEC-205 receptor expressed on the surface of a dendritic cell and the DEC-205 receptor expressed on the surface of a cancer cell' to a membrane scaffold protein, and then binding to the hydrophobic portion of the lipid constituting the shape of a lipid nanoparticle through hydrophobic binding via the membrane scaffold protein.
[0024] In the pharmaceutical composition of the present invention, the mRNA may preferably be an mRNA anticancer vaccine.
[0025] In the pharmaceutical composition of the present invention, the 'DEC-205 bound lipid nanoparticle' may preferably have a CpG agonist loaded therein.
[0026] In the pharmaceutical composition of the present invention, the pharmaceutical composition may preferably be a vaccine.
[0027]
[0028] The present invention is a pharmaceutical formulation (a type of carrier) capable of carrying an anticancer active mRNA vaccine, and the following effects can be expected.
[0029] (1) A dual-targeting mRNA vaccine targeting DEC-205 can simultaneously express antigens in DCs and tumor cells. This solves the problem of antigen loss within the tumor and CD8 + T cell response can be maximized.
[0030] (2) Unlike conventional mRNA vaccines that target only DCs, this technology can suppress immune evasion by inducing tumor cells to directly express antigens. As a result, even if cancer cells use strategies to reduce antigen expression or decrease MHC-I expression, CD8 + The T cell attack can continue.
[0031] (3) As antigen presentation is enhanced in DCs, antigens are also expressed in tumor cells, thereby CD8 + T cell activation is maximized. This can induce a more powerful immune response within the tumor microenvironment.
[0032] (4) By utilizing a targeting strategy with DEC-205 antibodies, the problem of non-specific accumulation in the liver associated with existing LNP-based mRNA vaccines can be resolved. Since the vaccine is selectively delivered to DC and tumor tissues, the concentration of the immune response is increased, and the anticancer effect can be enhanced.
[0033] (5) When combined with a Toll-like receptor (TLR) agonist, it can promote the maturation of DCs and induce the formation of long-term immune memory. Through this, it is possible to establish an anticancer vaccine platform capable of maintaining a continuous immune response beyond a one-time immune response.
[0034] (6) Compared to existing mRNA vaccines, the efficiency of antigen expression in tumors and lymph nodes is improved, so a strong immune response can be induced with a lower dose of mRNA. This can contribute to maximizing therapeutic effects while minimizing side effects.
[0035] The present invention can overcome the limitations of existing anticancer vaccines and contribute to establishing a next-generation cancer immunotherapy strategy through combination with immunotherapies and antibody-based therapies.
[0036]
[0037] Figure 1 is a schematic diagram showing the binding of mRNA@LNP and GrAb.
[0038] Figure 2 is a schematic diagram of the DEC-205 target GrAb (Grabber Antibody) prepared in this embodiment.
[0039] FIG. 3 shows a description of the corresponding portion of the sequences of sequence numbers 1 to 4 used in the present invention.
[0040] Figure 4 shows the results of evaluating the expression levels of DEC-205 on various cell surfaces.
[0041] Figure 5 shows the results of the characteristic analysis of the present invention's DEC-205 target GrAb (DecLNP), which is a dual-targeting GrAb-LNP.
[0042] Figure 6 shows the results of DEC-205-mediated endocytosis by DecLNP (analysis in cancer cells).
[0043] Figure 7 shows the results of DEC-205-mediated endocytosis by DecLNP (analysis in dendritic cells).
[0044] Figure 8 shows the recycling analysis results of DEC-205 after DecLNP treatment.
[0045] Figure 9 shows the results of the analysis of intracellular influx of DEC-205-mediated GrAb-LNPs.
[0046] Figure 10 shows the results of experiments on intracellular influx and receptor blockade of DEC-205-mediated GrAb-LNPs.
[0047] Figure 11 shows the results of the analysis of intracellular influx and expression of DEC-205-mediated mRNA.
[0048] Figure 12 shows the results of confirming selective mRNA delivery into tumors and lymph nodes using dual-targeting LNPs (DecLNP) (C57BL / 6 mouse model).
[0049] Figure 13 shows the results of confirming selective mRNA delivery into tumors and lymph nodes using dual-targeting LNPs (DecLNP) in a BALB / c mouse model.
[0050] Figure 14 shows the results of an in vivo analysis of DEC-205-mediated mRNA translation efficiency.
[0051] Figure 15 shows the results of confirming CpG ratio optimization in mRNA@LNP formulations.
[0052] Figure 16 shows the results of CpG ratio optimization and immune response analysis in mRNA@LNP formulations.
[0053] Fig. 17 is mOVA CPG This is the result of an antigen presentation activation analysis (in vitro) using @DecLNPs.
[0054] Figure 18 is a schematic diagram of a co-culture analysis experiment.
[0055] Figure 19 shows the results of an antigen-mediated OT-1 T cell activation analysis.
[0056] Figure 20 shows the results of antigen-specific tumor cell killing (Tumor Killing) analysis.
[0057] Figure 21 is an in vivo OVA-specific CD8 + This is the result of the T cell induction and CTL activity analysis.
[0058] Fig. 22 is a dual-targeting mOVA CpG This is the result of the analysis of the powerful anti-tumor effects of @DecLNPs.
[0059] Figure 23 shows the results of the analysis of the immune response within the tumor tissue.
[0060] Figure 24 shows the results of the full-field (confocal) image analysis for the analysis of CD8 / IFNγ killer T cells in tumor tissue.
[0061] Figure 25 shows the results of the analysis of immune responses in tumor drainage lymph nodes (TDLNs) and the spleen.
[0062] Fig. 26 is an mOVA CpG This is the result of the in vivo safety evaluation after administration of @DecLNPs.
[0063] Figure 27 shows the results of the evaluation of the antitumor efficacy of a low-dose dual-targeting vaccine.
[0064] Figure 28 shows the results of the analysis of the antitumor efficacy of a low-dose dual-targeting vaccine.
[0065] Figure 29 shows the results of evaluating the cell binding and mRNA delivery efficiency of DC-targeted lipid nanoparticles according to the helper lipid composition.
[0066]
[0067] The present invention relates to a DEC-205-targeted dual-targeting mRNA cancer vaccine and an anticancer immunotherapy technology utilizing the same. Cancer cells reduce the expression of target antigens as part of their immune evasion strategies, which is one of the major causes inhibiting tumor-specific immune responses. Furthermore, in the tumor microenvironment, the antigen presentation function of dendritic cells (DCs) is reduced, leading to CD8 + T cell activation is not effectively achieved.
[0068] To solve these problems, the present invention provides a technology that maximizes antigen presentation by delivering an mRNA vaccine to both DCs and tumor cells using dual-targeting lipid nanoparticles (DEC-205-targeting dual-targeting LNP, dLNP) that target the DEC-205 receptor. Figure 1 is a schematic diagram showing the binding of mRNA@LNP and GrAb.
[0069] DEC-205 is a receptor expressed not only in antigen-presenting cells (APCs), including dendritic cells, but also in some tumor cells; therefore, targeting it can simultaneously induce antigen expression in DCs and tumor cells. Accordingly, the present invention can preferably be applied to cancer cells expressing DEC-205.
[0070] Based on this, the present invention provides a pharmaceutical composition for the prevention or treatment of cancer in which a DEC-205 receptor is expressed on the surface of cancer cells, comprising a 'DEC-205 bound lipid nanoparticle' having an antibody or antibody fragment capable of binding to both a DEC-205 receptor expressed on the surface of dendritic cells and a DEC-205 receptor expressed on the surface of cancer cells,' and having mRNA loaded inside. In this case, the pharmaceutical composition may preferably be a vaccine.
[0071] In the above-mentioned antibody or antibody fragment capable of binding to both the DEC-205 receptor expressed on the surface of dendritic cells and the DEC-205 receptor expressed on the surface of cancer cells, the antibody may preferably be of the IgG type. Additionally, the antibody fragment may be, for example, scFv or Fab.
[0072] In the pharmaceutical composition of the present invention, the 'antibody or antibody fragment thereof capable of binding to both the DEC-205 receptor expressed on the surface of dendritic cells and the DEC-205 receptor expressed on the surface of cancer cells' may be bound to lipid nanoparticles, for example, through chemical bonding. At this time, there may be various types of chemical bonding for binding the 'antibody or antibody fragment thereof capable of binding to both the DEC-205 receptor expressed on the surface of dendritic cells and the DEC-205 receptor expressed on the surface of cancer cells' to lipid nanoparticles.
[0073] One example is the maleimide-thiol reaction, in which a maleimide functional group is introduced into the lipids of lipid nanoparticles, and then a chemical reaction is induced between the maleimide functional group and the thiol functional group of an antibody to form a chemical bond.
[0074] In addition, there is an amine-carboxyl reaction that forms a chemical bond between the carboxyl group (-COOH) present in the lipid of the lipid nanoparticle and the amine group (-NH2) of the antibody.
[0075] In addition, there is a click chemistry (CuAAC, SPAAC) reaction in which azide (-N₃) or alkyne (-C≡C) functional groups are introduced into the lipids of lipid nanoparticles and click-reactive functional groups are introduced into antibodies, and then chemical bonds are formed through a click reaction between them.
[0076] In addition, there is a hydrazine or oxime binding reaction in which an aldehyde functional group is introduced to the lipids of lipid nanoparticles and a hydrazine (-NH-NH₂) or oxime (-C=NOH) functional group is introduced to the antibody, followed by inducing a chemical reaction between them to form a chemical bond.
[0077] In addition, there is a Staudinger ligation reaction in which a phosphine functional group is introduced into the lipids of lipid nanoparticles and an azide (N₃) functional group is introduced into the antibody, and then a chemical reaction is induced between them to form a chemical bond.
[0078] At this time, since the specific chemical reaction conditions for attaching the above-mentioned 'antibody capable of binding to both the DEC-205 receptor expressed on the surface of dendritic cells and the DEC-205 receptor expressed on the surface of cancer cells, or an antibody fragment thereof' to lipid nanoparticles are well known, a detailed description thereof will be omitted.
[0079] Meanwhile, in the pharmaceutical composition of the present invention, the "antibody or antibody fragment thereof capable of binding to both the DEC-205 receptor expressed on the surface of dendritic cells and the DEC-205 receptor expressed on the surface of cancer cells" may be attached to lipid nanoparticles via a biopolymer, for example, a protein. Specifically, the "antibody or antibody fragment thereof capable of binding to both the DEC-205 receptor expressed on the surface of dendritic cells and the DEC-205 receptor expressed on the surface of cancer cells" may be, for example, attached to a membrane scaffold protein, and then attached to the hydrophobic portion of the lipid constituting the shape of the lipid nanoparticle through hydrophobic binding via the membrane scaffold protein. Since specific details regarding this can be found in Korean Registered Patent No. 10-2698524 (registration date August 20, 2024), a detailed explanation thereof will be omitted.
[0080] In the pharmaceutical composition of the present invention, the mRNA may preferably be an mRNA anticancer vaccine. The mRNA anticancer vaccine delivers mRNA encoding an antigen that is specifically or overexpressed in cancer cells into the body to induce an immune response targeting the corresponding antigen. Such a vaccine can be designed to suit the tumor characteristics of specific cancer types or patients. Unlike conventional cancer treatments (surgery, radiation, chemotherapy), it is a form of immunotherapy that induces the patient's immune system to directly attack cancer cells.
[0081] The mRNA loaded inside the lipid nanoparticles of the present invention is designed to contain antigen information by analyzing the genetic characteristics of cancer cells. This designed mRNA is generated as an antigen (specifically, an antigen protein) within ribosomes in dendritic cells or cancer cells and displayed on the surface of the dendritic cells or cancer cells. The antigen displayed on the surface is recognized by immune cells (dendritic cells, T cells, etc.), thereby activating an immune response. Subsequently, the activated T cells locate and eliminate the cancer cells.
[0082] Meanwhile, a CpG agonist may be loaded inside the lipid nanoparticles of the present invention. It was confirmed through the following experiment that the addition of CpG contributes to DC activation and the enhancement of antigen presentation function.
[0083] Existing LNP-based mRNA vaccines primarily targeted DCs to deliver antigens, and lacked strategies to induce an immune response by directly expressing antigens in the tumor cells themselves. However, by utilizing the technology of the present invention, antigen presentation is simultaneously enhanced in DCs and expressed in CD8 + T cell responses can be maximized. Through this, immune evasion caused by a lack of antigens within the tumor can be prevented, and a powerful anti-cancer immune response can be induced.
[0084] In this invention, the LNP surface is modified using the DEC-205 antibody, thereby inducing the effective delivery of mRNA to DCs and tumor cells. Furthermore, by promoting DC maturation through concomitant use with a Toll-like receptor (TLR) agonist, a more potent CD8 + It enables the induction of T cell responses. Through this, it resolves the problem of non-specific accumulation in the liver associated with existing LNP-based vaccines and maximizes selective antigen delivery within tumors and lymph nodes.
[0085] By utilizing this technology, the selective delivery efficiency within tumors and lymph nodes is increased compared to existing LNP-based mRNA vaccines, thereby improving antigen expression and CD8 + It can enhance T cell responses. Furthermore, the amplification of the anti-cancer immune response strengthens the formation of immune memory, allowing for the expectation of long-term anti-cancer effects. Ultimately, the anti-cancer vaccine platform of the present invention is a next-generation immunotherapeutic agent capable of overcoming the limitations of existing cancer vaccines.
[0086] In summary, the present invention develops a dual-targeting mRNA vaccine targeting DEC-205, which can induce a potent anti-cancer immune response by simultaneously expressing antigens in dendritic cells (DCs) and tumor cells. While existing LNP-based mRNA vaccines primarily target DCs to deliver antigens, if antigen expression within tumor cells is insufficient, CD8 + There is a high possibility that the T cell response will be limited. However, the vaccine platform of the present invention can maximize antigen presentation and suppress immune evasion by simultaneously targeting DCs and tumor cells.
[0087] In the experiment of one embodiment of the present invention described below, it was confirmed that an mRNA vaccine is selectively delivered to DCs and tumor cells by introducing a DEC-205 antibody onto the surface of an LNP. DEC-205 is a receptor with antigen capture function that is expressed in DCs and some tumor cells and is a target molecule that induces a strong immune response after mRNA delivery. The present vaccine expresses antigens in DCs and tumor cells through a DEC-205-targeted LNP (DecLNP) and antigen-specific CD8 + It is designed to maximize the T cell response.
[0088] Meanwhile, the lipid nanoparticles of the present invention can be loaded with mRNA (mRNA vaccine) encoding a tumor antigen as a type of formulation. The formulation of the pharmaceutical composition of the present invention can be formulated in a preferred form depending on the method of use, and it is particularly preferable to formulate it by adopting a method known in the art to provide rapid, sustained, or delayed release of the active ingredient after administration to mammals. Specific examples of formulations may include injections.
[0089] In addition, the dosage of the pharmaceutical composition of the present invention is preferably determined by considering the method of administration, the age, gender, and weight of the user, and the severity of the disease. For example, based on the active ingredient loaded, it may be administered one or more times per day at a dose of 0.000001 to 1,000 mg / kg (body weight). However, the above dosage is merely an example for illustrative purposes and may vary depending on the user's condition and the doctor's prescription.
[0090] In addition, the pharmaceutical composition of the present invention may further comprise pharmaceutically acceptable carriers, diluents, or excipients. Examples of usable carriers, excipients, or diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil, and one or more of these may be used. Additionally, if the preventive and therapeutic agent is a pharmaceutical, fillers, anticoagulants, lubricants, wetting agents, fragrances, emulsifiers, or preservatives may be additionally included.
[0091]
[0092] Hereinafter, the content of the present invention will be explained in more detail through the following examples and experimental examples. However, the scope of the present invention is not limited to the following examples and experimental examples, but includes variations of equivalent technical concepts.
[0093]
[0094] [Example 1: Preparation of 'nanolipid particles capable of simultaneously delivering antigens to cancer and dendritic cells' of the present invention and confirmation of their anticancer activity]
[0095] I. Experimental Objective
[0096] In this embodiment, we prepared DEC-205 targeted nanolipid particles capable of simultaneously delivering antigens to cancer cells and dendritic cells according to the present invention, and confirmed their anticancer activity.
[0097]
[0098] II. Experimental Materials and Methods
[0099] 1. Gene Synthesis and Cloning
[0100] The nucleotide sequences of the antigen protein and other genes to be encoded were optimized to minimize the use of rare codons using IDT’s codon optimization tool and further evaluated using algorithms from GenScript (Piscataway, NJ, USA). The optimized gene sequences were synthesized using commercial synthesis services; in this experiment, they were synthesized in the form of gBlocks by Genewiz Biotech (China).
[0101] Cloning was performed using sequence- and ligation-independent cloning. The high-fidelity PCR enzyme KOD Plus Neo DNA polymerase (TOKOD-401, Toyobo) was used for amplification of the vector and the inserted gene, and after amplification, the samples were digested with DpnI restriction enzyme (R017L, NEB) to remove methylated residues from the template plasmid. The prepared insertion fragment and vector fragment were processed to form complementary ends and then assembled using T4 DNA polymerase (M0203S, NEB) to ensure smooth ligation. The assembled recombinant plasmid was transformed into E. coli TOP10 competent cells, and sequencing analysis was performed on selected colonies to verify the accurate insertion and sequence.
[0102]
[0103] 2. Expression and Purification of GrAb Antibodies
[0104] ExpiCHO-S cells were used for the expression of GrAb (antibody-Apoprotein fusion protein, e.g., a fusion of the Fc domain of a DEC-205 target antibody and Apolipoprotein A1). ExpiCHO-S cells were 6.0 × 10⁶ 6 After dispensing into culture flasks at an initial density of cells / mL, neutralization transformation was performed the following day. ExpiFectamine CHO reagent (A14524, Thermo Fisher) was used for transformation, and two plasmids expressing the heavy and light chains of GrAb were prepared by mixing them in a 1:1 mass ratio. The total DNA amount of the two plasmids was 1 μg per 1 mL of culture medium and then added to the cells. The transformed cells were cultured for 13 days in a shaking incubator (120 rpm) under conditions of 37°C and 8% CO₂.
[0105] After culturing for 13 days, the culture supernatant was collected and centrifuged at 7,000 g for 30 minutes at 4°C. The supernatant was then filtered through a 0.22 μm pore PES membrane filter to remove cellular residues. The GrAb protein was purified by passing the filtered supernatant through a protein A affinity chromatography column. The antibody protein bound to the column was eluted with a low pH buffer, and the recovered eluent was dialyzed using a dialysis membrane with a molecular weight limit of 1 kDa (MWCO) to replace the eluent with a storage buffer (e.g., PBS) and remove impurities and residual eluent components. The concentration of the purified GrAb protein was measured, and it was subsequently used in the lipid nanoparticle surface binding process.
[0106]
[0107] 3. mRNA Design and In Vitro Transcription
[0108] Codon-optimized target gene sequences (such as anticancer antigens and immunostimulatory proteins) were cloned into mRNA expression vectors and used as templates for in vitro transcription (IVT). In this experiment, Takara Bio’s mRNA Template cloning kit vector (cat. #6143) was used. This vector contains a T7 promoter, 5' and 3' untranslated regions (UTRs), and a Poly(A) tail consisting of 100 adenines. An IVT template plasmid was constructed by inserting the optimized gene sequences into this vector.
[0109] The constructed template plasmid was fully linearized with HindIII-HF restriction enzyme and used for the IVT reaction. mRNA synthesis was performed using Takara Bio's IVTpro™T7 mRNA synthesis kit (cat. #6144) according to the manufacturer's protocol. For capping, CleanCap Reagent AG (3' OMe) was added to the transcription mixture to form a 5' Cap_1 structure. During the transcription reaction, N1-methyl-ψuridine triphosphate was added at an equal molar concentration instead of ribonucleotide UTP to reduce the immune response and improve mRNA stability. Additionally, when fluorescently labeled mRNA was required for tracking and quantification, a portion of the UTP was replaced with Cy5-UTP (e.g., transcribed by mixing N1-methyl-ψuridine to Cy5-UTP in a 3:1 molar ratio). The synthesized mRNA products underwent purification procedures recommended by the kit, such as DNase treatment and LiCl precipitation, followed by purification using the Monarch RNA Cleanup kit. The purified mRNA was dissolved in RNase-free sterile distilled water to a final concentration of 1 mg / mL and stored at -80 ℃ until use. If necessary, the quality of the mRNA was assessed using a NanoDrop spectrometer to determine purity (A 260 / A 280 The concentration and size were checked, and the size and integrity were examined by agarose gel electrophoresis.
[0110]
[0111] 4. Preparation of Lipid Nanoparticles (LNPs) and Formation of GrAb-LNPs
[0112] mRNA-loaded lipid nanoparticles (LNPs) were formed by micromixing a lipid mixture in the ethanol phase with a nucleic acid solution in the aqueous phase. The ethanol phase was composed to include ionizable lipids, phospholipids, cholesterol, and lipid-polymers. Specifically, the cationic lipid SM-102, the phospholipid DSPC, cholesterol, and the PEG-lipid DMG-PEG2000 were mixed in a molar ratio of 50:38.5:10:1.5 and dissolved in ethanol to achieve a total lipid concentration of 6.25 mM. The DiD dye, a reagent for fluorescence tracking, was added to the ethanol phase at a ratio of 1 mol% relative to the total moles of lipids to introduce fluorescent labeling to the LNPs. The aqueous phase was prepared by dissolving the desired mRNA in 25 mM sodium acetate (pH 3.5); under conditions requiring the co-loading of an adjuvant, synthetic CpG ODN 1826 was mixed with the mRNA in the corresponding buffer solution. At this time, the ratio of ionized lipids to phosphate groups (N / P) was fixed at 6, so that the amount of positively charged lipids was six times greater than the amount of negatively charged nucleic acids. The ethanol phase and the aqueous phase were combined at a volume ratio of 1:3 using a dedicated nanoparticle preparation device (NanoAssemblr Ignite, Precision Nanosystems). As the two solutions met and rapidly mixed in the microchannel, lipid nanoparticles were spontaneously formed, and mRNA molecules were encapsulated inside the formed lipid nanoparticles. The resulting mRNA-LNP solution was used immediately or temporarily stored at 4°C.
[0113] To prepare GrAb-LNP, mRNA-LNP prepared by the above method was mixed with purified GrAb protein to attach GrAb to the surface of the LNP. Mixing was performed by adjusting the mass ratio of mRNA to GrAb protein under various conditions (e.g., 5:1, 2:1, 1:1, 1:2, 1:5), with a mass ratio of 1:1 used as the representative condition. After adding a calculated amount of GrAb protein solution to the mRNA-LNP solution, the mixture was reacted (incubated) at 37°C for 30 minutes to allow sufficient interaction between GrAb and lipid nanoparticles. To remove excess unbound GrAb remaining in the GrAb-LNP solution obtained after the reaction, centrifugal concentration was performed using an ultrafiltration filter with a molecular weight cutoff limit (MWCO) of 1 MDa. The GrAb-LNP solution was placed in the corresponding ultrafilter and centrifuged at 12,000 g for 10 minutes, after which the filtration residue (retentate) was resuspended in PBS. This concentration-resuspension process was repeated twice to wash away free GrAb. The purified GrAb-LNP formulation was stored at 4 ℃ or used immediately for subsequent experiments.
[0114]
[0115] 5. LNP Characterization (Size, Zeta Potential, Encapsulation Rate, etc.)
[0116] Various analyses were performed to determine the physicochemical properties of the formed lipid nanoparticles. Particle size distribution and polydispersity index (PDI) were measured using dynamic light scattering (DLS) techniques. Specifically, the prepared LNP samples were appropriately diluted in sterile filtered PBS and then injected into a cuvette of a Zetasizer Nano ZS analyzer (Malvern Instruments, UK) to determine the average number-average diameter (Z-avg) and PDI values at 25 °C. Zeta potential was also measured using the same instrument to evaluate the surface charge characteristics of the particles.
[0117] The efficiency of mRNA encapsulation within the LNP was verified using RiboGreen fluorescence analysis. Since RiboGreen reagent binds to single-stranded RNA and emits strong fluorescence, the fluorescence signal was measured by treating the unencapsulated RNA remaining outside the LNP with the reagent. Subsequently, the LNP was disrupted using a surfactant such as Triton X-100, and the fluorescence signal of the released total RNA was measured again. The mRNA encapsulation rate was calculated by comparing the ratio of the two values.
[0118] To analyze the binding of purified GrAb to the LNP surface, the sample was fed into a Size Exclusion Chromatography (SEC) Increase 10 / 300 GL SEC column to identify peaks of protein-bound LNPs, and the presence of GrAb was verified by collecting the corresponding fraction and analyzing it via SDS-PAGE. Additionally, the concentration of LNP particles per unit volume was measured using a NanoSight NS300 (Malvern) nanoparticle tracking analyzer (NTA), and the total protein content in the sample was determined using the BCA protein quantification method to estimate the number of GrAb molecules bound to a single LNP (calculated by converting the measured total protein content into the number of molecules corresponding to Avogadro's number and dividing by the total number of particles).
[0119] The morphology and structure of the LNPs were observed using cryo-electron microscopy (cryo-TEM). A small amount of LNP sample was placed on a grid of copper and preserved by cryo-freezing. The LNP particles formed on the grid were directly observed using a Tecnai F20 G2 (200 kV) field emission transmission electron microscope from FEI, and the particle morphology was evaluated. Additionally, to evaluate the stability of the prepared LNPs, size changes were monitored by performing DLS measurements at regular intervals while storing them at 4°C for one week.
[0120]
[0121] 6. Cell Experiments (Cell Lines and Culture Conditions)
[0122] The cell lines used in the experiment are as follows. CT26.CL25 cells are a mouse-derived colorectal cancer cell line that is a mutant line into which a gene to express the OVA antigen has been introduced (ATCC CRL-2639). MC38 is a mouse colorectal cancer cell line, and MC38-OVA is a modified cell line established by infecting MC38 cells with a lentivirus containing the full-length Ovalbumin (OVA) gene. 4T1-Luc is a luminescently labeled cell line formed by transfecting the firefly luciferase gene into the human breast cancer cell line 4T1 (ATCC CRL-2539-LUC2). RAW264.7 is a mouse-derived macrophage line, and MutuDC1940 is a mouse dendritic cell line (MutuDC1940, ABM, Canada). These cell lines were used after being distributed or donated by each accredited cell line supplier (MC38 and MC38-OVA were provided by Professor Jae-Hyung Park of Sungkyunkwan University).
[0123] Cell culture was performed according to the recommended conditions for the respective cell lines. CT26.CL25, 4T1-Luc, and RAW264.7 cells were cultured in RPMI-1640 (Welgene, South Korea) as the basal medium, while MC38 and MC38-OVA cells were cultured in high-glucose DMEM medium (Welgene). MutuDC1940 dendritic cell lines were cultured in IMDM medium (Gibco). All media were prepared as complete media supplemented with 10% (v / v) heat-inactivated FBS and 1% (v / v) Antibiotic-Antimycotic mixture (pencillin 100 U / mL, streptomycin 100 μg / mL, amphotericin B 0.25 μg / mL). Cells were cultured in a humidified incubator supplied with 5% CO₂ at 37°C, and were passaged whenever the cell density in a suitable culture vessel reached 70-80%. All cell experiments were performed with the cultured cells in the log phase, and the cells were conditioned to a fresh environment by changing the medium prior to the experiment.
[0124]
[0125] 7. Receptor Expression Analysis and Internalization Assessment
[0126] Receptor-mediated binding assays were performed by flow cytometry (FACS) to confirm the cell binding specificity and efficiency of DEC-205-targeting LNPs. MC38 and CT26.CL25 tumor cells were each sampled at 1 × 10⁶, including representative cells expressing the DEC-205 receptor (e.g., MutuDC1940 dendritic cells) and control cells with low expression (e.g., RAW264.7 macrophages). 6Cells were prepared individually. The cells were washed with PBS supplemented with 1% BSA and suspended. Each sample was then treated with a DiD fluorescence-labeled mRNA-LNP formulation (cLNP: antibody-free LNP, iLNP: isotype antibody-LNP, dLNP: DEC-205 GrAb-LNP) to achieve a final mRNA concentration of 400 ng / mL. The cells were incubated at 37°C for 30 minutes to allow sufficient binding and absorption of the LNPs, after which non-specifically attached particles were removed by washing three times with cooled PBS. Subsequently, the cell binding rate of LNPs was evaluated by measuring the DiD fluorescence intensity of each cell using a CytoFLEX flow cytometer (Beckman Coulter).
[0127] Receptor blockade experiments were also conducted in parallel under the same conditions. Before reacting cells with LNP, an excess amount of the anti-DEC-205 monoclonal antibody (an epitope-recognizing antibody identical to the GrAb antibody used in other experiments) was reacted with the cells at 37°C for 1 hour to saturate the DEC-205 receptors on the cell surface. Subsequently, DiD-labeled LNP was applied in the same manner, followed by the washing and flow cytometry procedures described above. Through this competitive binding assay, the specific binding to the DEC-205 receptor was verified (confirming whether a decrease in LNP binding occurred upon receptor blockade).
[0128] Changes in DEC-205 receptor expression and internalization were evaluated by measuring DEC-205 protein levels on the cell surface before and after LNP treatment using flow cytometry. MutuDC1940 dendritic cells were used to confirm the internalization of the target receptor following treatment with GrAb-LNP (dLNP). Cells were treated with dLNP at a concentration of 400 ng mRNA / mL and incubated at 37°C for 30 minutes; after removing the LNP, the cells were continued to be cultured in a 37°C incubator. Cells were collected at 4, 8, and 24 hours after treatment, washed with PBS, and the DEC-205 on the cell surface was stained using an anti-DEC-205 antibody (either linked to a fluorescently labeled secondary antibody or using a directly fluorescently labeled antibody). Changes in mean fluorescence intensity (MFI) were monitored by measuring the stained cells using a flow cytometer. As a result, compared to the initial expression level of DEC-205 on the cell surface, the surface DEC-205 level in the dLNP-treated group decreased in a time-dependent manner and subsequently partially recovered, demonstrating that LNP is drawn into the cell via DEC-205 receptor-mediated endocytosis, and that the intracellular translocation and recycling of the receptor occur.
[0129]
[0130] 8. In vitro fluorescence microscopy and luminescence analysis
[0131] The intracellular uptake and distribution of mRNA delivered via LNPs were observed using confocal fluorescence microscopy. Experiments were performed using the previously prepared mRNA-loaded LNPs labeled with Cy5-UTP. MC38, CT26.CL25, and MutuDC1940 cells were placed in 5 × 10⁴ glass-bottomed 35 mm confocal microscopy culture dishes (SPL product), respectively. 5Cells were seeded individually and cultured in attachment at 37°C in 5% CO₂ for 24 hours. The following day, the medium was removed, and LNPs loaded with Cy5-labeled mRNA were treated on each plate at 37°C for a set period (e.g., 2 hours). After treatment, the cells were washed several times with PBS to remove any remaining particles in the medium and excess reagents attached to the cell exterior. Subsequently, the cells were fixed with 4% paraformaldehyde, and Hoechst 33342 solution was applied to stain the nuclei. Finally, each sample was observed using a Leica TCS SP5 laser confocal microscope (Leica Microsystems, Germany). Hoechst's blue fluorescence (nuclear location) and Cy5's red fluorescence (mRNA location) were captured simultaneously across different wavelengths to visualize the presence of mRNA delivered into the cytoplasm via LNPs. If necessary, Z-stack images were acquired under the same conditions, and detailed intracellular distribution was confirmed through 3D reconstruction.
[0132] Luciferase expression analysis (luminescence analysis) was performed to confirm the functional expression (protein expression) of mRNA delivered via LNP. Using firefly luciferase (FLuc) mRNA as a reporter, mRNA delivery efficiency was measured by quantifying the post-translational enzyme activity expressed within the cell. MC38, CT26.CL25, and MutuDC1940 cells were seeded into 48-well cell culture plates by species and cultured at approximately 70–80% density for 24 hours; subsequently, LNP formulations loaded with mFLuc were administered to each well. The dosage was set to LNP equivalent to 62.5 ng of mRNA per well, and the cells were treated at 37°C for 2 hours. After 2 hours, the medium was removed from each well, gently washed with PBS, and replaced with fresh medium for an additional 24 hours of cell culture. After 24 hours, the medium was removed to prepare for the luminescence substrate reaction. First, to extract cells from each well, 45 μL of Promega’s Cell Culture Lysis Reagent (5X concentration) was added per well to lyse the cells. The well-mixed lysate was transferred to a white 96-well plate, and 100 μL of luciferase substrate solution (Promega Luciferase Assay Reagent) was added. The luminescence signal was measured using a GloMax microplate luminescence reader (Promega, USA). The luminescence value of each sample was converted into a relative light intensity compared to an untreated control group and used as a quantitative indicator of mRNA delivery and expression.
[0133] Additionally, to confirm antigen protein expression, mRNA encoding the OVA antigen was loaded onto LNPs and treated to cells using the same method as above (e.g., 2 μg / mL, 20 hours). OVA-derived peptide-MHC I complex (H-2K) expressed on the cell surface after treatment b -OVA 257-264A monoclonal antibody (SIINFEKL / H-2K) that specifically recognizes ) b Staining and flow cytometry were performed using specific antibodies. Through this, the antigen presentation ability of mOVA introduced via LNP was confirmed in vitro.
[0134]
[0135] 9. In vivo administration (establishment of mouse tumor model and drug treatment)
[0136] All animal experiments were conducted under the approval of the Institutional Animal Health Committee (IACUC) (KIST Approval No.: KIST-2022-04-072). 6-8 week old BALB / c mice (female) and C57BL / 6 mice (male) were used in the experiments. The experimental animals were purchased from Orient Bio (Seongnam), South Korea, and housed in a disease-free environment; they underwent an environmental acclimatization period of at least one week prior to the experiments.
[0137] The tumor transplantation model was constructed in two forms.
[0138] (1) Subcutaneous xenograft tumor model: 1 × 10⁶ MC38 tumor cells in the subcutaneous fat layer of the left flank of 7-week-old C57BL / 6 male mice 6 Inject the tumor cells suspended in 100 μL of PBS, or inject 1 × 10⁶ CT26.CL25 tumor cells into BALB / c male mice. 6 Tumors were induced by subcutaneous inoculation of 100 μL each.
[0139] (2) Orthotopic tumor model: After anesthetizing 8-week-old female BALB / c mice, 1 × 10⁶ 4T1-Luc cells were deposited in the mammary fat pad of the fourth mammary gland. 5 Primary tumors were induced in the mammary glands by injecting the cancer cells suspended in 60 μL of PBS. In this manner, a solid tumor formed at the inoculation site approximately 12 weeks after the injection of cancer cells. Tumor size was measured every 23 days using a digital caliper, and tumor volume was calculated using the general formula 0.5 × (width) 2It was calculated using × (vertical length).
[0140] Nanoparticle administration was performed when the tumor size reached the level required for the experiment. Intravenous (IV) was selected as the route of drug administration for all drugs. After gently restraining the mice, the sample was slowly injected into the tail vein using a pre-heparinated 1 mL syringe and a 30-gauge needle. For the biodistribution experiment, the average tumor size was approximately 100 mm 3 At the time of reaching [date], DiD fluorescence-labeled mFLuc mRNA-loaded LNP was administered (mRNA-based dose 0.5 mg / kg per mouse, administration volume 100 μL). For the therapeutic efficacy evaluation experiment, the therapeutic sample was administered repeatedly on days 4 and 9 after tumor cell injection. For example, in a C57BL / 6 mouse model with MC38 tumors, to compare with the PBS control group or the control LNP (cLNP) group without an immunoactivator, the dLNP (DEC-205 GrAb-LNP) formulation loaded with mOVA + CpG was administered IV twice at a dose of 0.75 mg / kg (mRNA-based). In the BALB / c mouse 4T1-Luc stereotactic model, since tumors grow more aggressively, interval administration was performed a total of four times on days 4, 9, 14, and 19. During this time, a relatively low dose group with an mRNA dose of 0.4 mg / kg was also established to evaluate efficacy. All mice were closely monitored during the administration period, and body weight and tumor volume were measured every other day to record changes following drug administration (particularly, body weight fluctuation is an indicator of systemic toxicity).
[0141]
[0142] 10. Tissue analysis and fluorescence / luminescence signal measurement
[0143] Biodistribution Analysis: After intravenously administering fluorescently labeled LNP, mice were anesthetized at specific time points to capture in vivo fluorescence images. In this experiment, near-infrared (NIRF) fluorescence was acquired non-invasively using a PerkinElmer IVIS Lumina Series III fluorescence imaging device. Mice were fixed in a dorsal position, and filtration settings optimized for DiD fluorescence (excitation 640 nm, emission 680 nm) were applied to obtain images over time from 0 hours (immediately after administration) to 24 hours. After sacrificing all mice at the 24-hour mark, major organs were collected to analyze organ-specific fluorescence and luminescence. The excised organs were washed with PBS to remove surface blood and individually wrapped in clear film; the organs included tumors, tumor-regional lymph nodes (TDLN), liver, spleen, lungs, kidneys, and hearts. These organs were placed back into the IVIS device, and organ-specific fluorescence images were acquired under the same conditions to evaluate ex vivo fluorescence distribution.
[0144] Bioluminescence imaging was also performed on the same organs to confirm the expression patterns of luciferase mRNA delivered via LNP. Each collected organ was placed in a 24-hole multi-sample dish and immersed in a D-luciferin solution (e.g., PBS solution containing 4 mM D-luciferin and 2 mM ATP) for 5 minutes to allow the substrate to diffuse within the tissue. Subsequently, the IVIS device was switched to the luminescence mode to capture the bioluminescent signals emitted from the organs. The acquired fluorescence and luminescence image data were quantified using Living Image software (PerkinElmer). Specifically, regions of interest (ROIs) of the same size were designated for each organ region, and the total fluorescence and total luminescence indices were calculated and compared based on relative signal intensity relative to the control group.
[0145] Tissue Section Fluorescence Analysis: To observe the microdistribution of nanoparticles within the tissue in greater detail, tumor and lymph node tissues excised from the stomach were prepared as frozen sections. Frozen blocks were created by immersing the tissues in an OCT compound cryopreserved at -80°C, and serial sections 10 μm thick were acquired using a cryostat. The sections were fixed with acetone or 4% PFA at room temperature, washed with PBS, and treated with Hoechst 33342 stain (1:1000 dilution) to counterstain the nuclei. The slides were then mounted, and the prepared specimens were observed using a fluorescence microscope (Thermo Fisher EVOS M5000, etc.). By confirming whether the blue signal of the cell nuclei and the DiD fluorescence signal of LNPs (red) overlapped within the tissue, the cellular or tissue regions where the nanoparticles were primarily distributed (e.g., cells within tumor tissue or sites within lymph node structures) were identified. If necessary, additional immunofluorescence staining was performed on the same samples to analyze the coexistence patterns of specific cell markers and LNPs.
[0146]
[0147] 11. T Cell Response Analysis (Co-culture and Flow Cytometry)
[0148] Isolation and Activation of T Cells: To evaluate the anticancer immune response following nanoparticle administration, T lymphocytes were isolated in vitro and functional analyses were performed. Spleens were aseptically excised from 8-week-old C57BL / 6 mice, completely crushed with a plunger in cold PBS in a Petri dish, and a single-cell suspension was obtained by filtering through a 70 μm cell strainer. To remove red blood cells, RBC lysis buffer (BioLegend) was added and left for 5 minutes, after which it was neutralized and washed with PBS. The remaining cells were recovered by centrifugation (300 g, 5 min), and CD8 +CD8 using a T cell negative isolation kit (Miltenyi Biotec, Germany) and a MACS LS column + T lymphocytes were isolated. The isolated immature T cells were stimulated by mixing them with Dynabeads Mouse T-Activator CD3 / CD28 magnetic beads at a bead-to-cell ratio of 1:1 per cell. Stimulation was performed at 1 × 10⁶ in a 24-well plate. 6 The procedure was carried out by culturing cells at a concentration of cells / mL. For immune cell culture, Advanced RPMI-1640 (Gibco) containing 10% FBS was prepared by adding recombinant mouse IL-2 (e.g., 20 U / mL) and 2-mercaptoethanol (0.05 mM). Cells were cultured at 37 °C under 5% CO₂ conditions for 4 days to induce activation. After 4 days, all Dynabeads were removed from the reaction mixture using a magnet, and the thus obtained activated CD8 + T cells were subsequently used in co-culture experiments. (If necessary, early activation markers such as CD69 and CD25 were checked using flow cytometry to verify that the T cells were successfully activated.)
[0149] Evaluation of T-cell activation by dendritic cell-T-cell co-culture: To confirm whether the previously isolated and activated T cells proliferate and become activated in response to antigens presented via nanoparticles, a co-culture experiment was performed using MutuDC1940 dendritic cells and OT-I T cells. CD8 derived from OT-I mice + T cells are OVA 257-264 Since it possesses a T-cell receptor that specifically recognizes the peptide (SIINFEKL), it will be activated upon receiving antigen presentation from dendritic cells administered mOVA (OVA protein-coding mRNA). First, MutuDC1940 cells were placed in a 48-well plate at a rate of 2 × 10⁶ per well. 4After aliquoting and attaching to the cells, LNP samples loaded with mOVA and CpG (e.g., cLNP control, dLNP experimental group) were treated at a final concentration of 2 μg / mL for 20 hours. After 20 hours of treatment, the medium was removed and the cells were washed once, followed by the previously prepared OT-I CD8 + 1 × 10 T cells per well 5 They were added in a ratio of [number]. T cells and dendritic cells were co-cultured in the same well for 48 hours. After 48 hours, both suspended and adhered cells were collected, suspended in FACS buffer (PBS + 1% FBS), and T cell proliferation and the expression of functional markers were evaluated via flow cytometry. The degree of T cell proliferation could be confirmed by generational staining dilution if the T cells were pre-stained with CellTrace Far Red prior to co-culture, or by analyzing intracellular staining for the Ki-67 proliferation marker after 48 hours. The degree of T cell activation was quantified by measuring intracellular expression of cell surface CD44 (memory / activation marker), CD69, and the immunocytokine IFN-γ using multicolor flow cytometry. Through these co-culture experiments, it was confirmed that dendritic cells treated with dLNP proliferated and activated T cells more effectively than those treated with cLNP.
[0150] Measurement of the tumor cell killing ability of cytotoxic T cells: To determine how efficiently tumor cells treated with antigens and immunostimulants via nanoparticles are killed by antigen-specific T cells, a tumor-CTL killing co-culture experiment was conducted. As target tumor cells, MC38 cells (non-OVA expressing) and general CD8 T cells were used instead of MC38-OVA cells expressing the OVA antigen. In this system, even if the delivered mOVA is expressed in MC38 cells, tumor cell killing does not occur because the T cells introduced into the co-culture lack antigen specificity. On the other hand, if OT-I T cells co-cultured with dendritic cells are additionally co-cultured with tumor cells, antigen-specific CTLs activated from the dendritic cells can recognize and kill the tumor cells. Therefore, a two-stage co-culture was utilized in this experiment: First, activated T cells were obtained through the aforementioned dendritic cell-OTI culture, and these were re-co-cultured with MC38 tumor cells.
[0151] MC38 cells were stained with CellTrace Far Red dye prior to co-culture (cells were permanently dyed by treating at a concentration of 5 μM per cell for 20 minutes and then washing). The stained MC38 cells were placed in 48-well plates at a concentration of 2 × 10⁶ per well. 4 Cells were aliquoted and incubated at 37°C. Next, MC38 cells in each well were treated with LNPs loaded with mOVA+CpG (control cLNP and target dLNP) at a concentration of 2 μg / mL and cultured for 20 hours. Subsequently, the medium was removed and washed once with PBS, after which the T cells activated in the previous step were introduced. T cells were administered under different effector:target (E:T) ratio conditions relative to MC38; for example, the E:T = 5:1 condition corresponds to 1 × 10⁶ T cells. 5 The condition for insertion of 2 × 10 T cells is E:T = 10:1. 5 This corresponds to the addition of dogs. After adding T cells, they were co-cultured at 37°C for 24 hours to induce tumor cell killing by CTLs.
[0152] After 24 hours, the suspended cells were collected, and the attached MC38 cells were separated using trypsin, combined, and all cells were retrieved. The retrieved cells were washed with PBS to prepare them for FACS analysis, and the number of Far Red staining-positive cells was counted. The number of Far Red-positive cells in the MC38 cell group without co-culture treatment was considered 100% viable, and the number of remaining Far Red-positive cells in the co-culture group was calculated as a survival percentage relative to this. Additionally, the cytotoxic effect induced by T cells was confirmed by observing the wells of each condition under a microscope and comparing the densities of adhered cells. Through these in vitro cytotoxic activity analyses, it was found that tumor cells treated with dual-target dLNP showed higher CD8 levels compared to cLNP. + It was verified that the killing rate by T cells significantly increased.
[0153]
[0154] 12. Toxicity Assessment (Blood Analysis and Histopathology)
[0155] To evaluate the systemic toxicity and safety of the developed nanoparticle vaccine, clinical indicators were observed and biochemical analyses were performed during the animal experiment period.
[0156] Body weight monitoring: Body weight was periodically measured for all mice in the administration and control groups during the treatment period to check for any rapid weight loss or abnormal signs resulting from the administration of the sample.
[0157] Blood and Serum Analysis: At the end of the final experiment (e.g., 21 days after the last administration), mice were sacrificed, and whole blood was collected from the heart. A portion of the collected whole blood was stored in tubes containing EDTA for a complete blood count (CBC), while the remainder was placed in standard SST tubes, coagulated at room temperature, and then centrifuged at 1,200 rpm for 20 minutes to separate the serum. Serum chemical analysis was performed using the separated serum samples, with major measurements including liver function indicators such as AST (GOT), ALT (GPT), and ALP (alkaline phosphatase); kidney function indicators such as blood urea nitrogen (BUN) and creatinine; and nutritional metabolism indicators such as total protein. In the hematological test (CBC), leukocyte counts (total white blood cell count and differential count: lymphocytes, monocytes, etc.) and erythrocyte counts (red blood cell count, hemoglobin concentration (Hgb), hematocrit, platelet count, etc.) were measured. These blood and biochemical analyses were commissioned to external specialized analytical laboratories to ensure reliability, and all values were compared to a control group.
[0158] Histopathological analysis: To evaluate whether repeated administration of nanoparticles caused histological changes or damage to major organs, major organs (liver, kidney, spleen, lung, heart, etc.) excised at the end of the experiment were fixed in a 10% neutral formalin solution for 24 to 48 hours. The fixed organs were paraffin-embedded to create blocks, and tissue sections approximately 4 μm thick were prepared using a microtome. After transferring the sections to Sood Slides, the paraffin was removed and the sections were rehydrated to perform hematoxylin-eosin (H&E) staining. The stained slides were mounted and observed under a light microscope to determine any abnormalities in the tissue structure. Particularly in the case of liver tissue, toxic changes due to nanoparticle administration were a concern; therefore, the liver tissues of the administration group were carefully examined for signs of inflammatory infiltration, cellular degeneration, or necrosis. Additionally, if necessary, apoptosis analyses such as TUNEL staining were performed on tumor tissues to observe tissue changes associated with the therapeutic effect.
[0159] Through such comprehensive toxicity evaluations, it was confirmed that the developed DEC dual-target GrAb-LNP nanoparticle system does not cause significant damage to major organs in vivo even with repeated administration, and that side effects such as hepatotoxicity are significantly reduced compared to existing systems. In addition, changes in immune cell balance and biochemical levels in the blood were maintained at control levels, thereby proving the safety of this nanovaccine platform.
[0160]
[0161] III. Experimental Results
[0162] 1. Preparation of DEC-205 Targeted GrAb-LNP (DecLNP)
[0163] In this example, GrAb-lipid nanoparticles (GrAb-LNP) capable of binding to DEC-205 were prepared. Our approach involved preparing a recombinant protein called GrAb (Grabber Antibody), which consists of two functional domains: a target antibody domain and an apolipoprotein, and then conjugating it with LNP.
[0164] Figure 2A is a schematic diagram of the DEC-205 target GrAb (Grabber Antibody) prepared in this embodiment. The apolipoprotein of the GrAb promotes the formation of a protein corona around the LNP, similar to "grabbing" the LNP, thereby enhancing specificity. NLDC-145 was used as the antibody for the DEC-205 target model, and ApoA1 and ApoE3 were selected as the apolipoproteins.
[0165] DEC-205-targeted GrAbs were constructed as follows. VH and VL (variable heavy chain and variable light chain) from the NLDC145 antibody were utilized, and a so-called 'chimeric antibody (ximab) form' was used, in which the CH and CL portions used sequences of Human IgG1. IgH-ApoA1 (Sequence No. 2) and IgH-ApoE3 (Sequence No. 3), in which the antibody heavy chain is bound to an apolipoprotein, were constructed, respectively (Fig. 2B). These are forms in which an apolipoprotein is bound to IgH; for IgH (Sequence No. 4), VH derived from NLDC145, which is an antibody that binds to DEC-205, was used. Additionally, IgL (Sequence No. 1), which encodes the antibody light chain, was constructed using VL derived from NLDC145, which is an antibody that binds to DEC-205 (Fig. 2B). FIG. 3 describes the corresponding domain region among each sequence in sequence numbers 1 to 4 of the present invention.
[0166] GrAb was expressed and purified using the ExpiCHO system to obtain yields of approximately 155 mg / L for ApoA1 and approximately 37 mg / L for ApoE3 (Fig. 2C). LNP and GrAb were incubated at 37°C for 0.5 hours to display antibodies on the surface of LNP via apolipoprotein-mediated interactions (Fig. 2D).
[0167]
[0168] 2. Evaluation of DEC-205 expression levels
[0169] We aimed to evaluate the expression levels of DEC-205 on various cell surfaces. Figure 4 shows the results of evaluating DEC-205 expression levels on various cell surfaces. The expression levels of DEC-205 were evaluated in CT26 (colorectal cancer cell line), CT26.CL25 (colorectal cancer cell line), MC38 (colorectal cancer cell line), 4T1-Luc (breast cancer cell line), MutuDC1940 (dendritic cell line), and RAW264.7 (macrophage cell line) via flow cytometry. Figure 4 shows the results of evaluating DEC-205 expression levels on various cell surfaces. In Figure 4, the gray histogram on the left represents the isotype control, and the dark gray histogram on the right represents the experimental group treated with the APC-conjugated DEC-205 antibody. The experimental results confirmed that DEC-205 was overexpressed in colorectal cancer, breast cancer, and dendritic cell lines. In contrast, it was confirmed that DEC-205 was not overexpressed in macrophages.
[0170]
[0171] 3. Characterization of DEC-205 Target LNP (DecLNP)
[0172] To evaluate the characteristics of LNPs targeting DEC-205, a characteristic analysis experiment was performed on the DecLNP of the present invention, which is a dual-targeting GrAb-LNP. Figure 5 shows the result of the characteristic analysis of DecLNP, which is a dual-targeting GrAb-LNP.
[0173] - Fig. 5A: The size stability of GrAb-LNPs was measured at different mass ratios and analyzed over various time periods after storage at 4°C. As a result of particle size and surface charge analysis (DLS, Zeta potential) of DecLNPs, stable particle characteristics were confirmed.
[0174] - Fig. 5B: Antigen expression efficiency was evaluated through luminescence intensity measured in MutuDC1940 cells on day 7 after treatment with GrAb-LNPs. Experimental results confirmed that the most stable sustained expression was achieved when the mass ratio of mRNA to GrAb antibody was 1:1.
[0175] - Figure 5C: The mRNA encapsulation efficiency of GrAb-LNPs at different mass ratios was measured using the RiboGreen assay. The results of the mRNA encapsulation efficiency analysis (RiboGreen assay) confirmed that DecLNP can effectively protect and deliver mRNA.
[0176] - Fig. 5D: Representative images of ConLNPs (Control LNPs) and DecLNPs (DEC-205 target LNPs) observed by cryo-electron microscopy (Cryo-TEM). They were compared at a mass ratio of 1:1, with a scale bar of 100 nm. It was confirmed that when the Grab antibody was attached, they maintained a spherical shape and no protein-mediated aggregation occurred.
[0177] - Figure 5E: To measure the insertion rate of Cy5-GrAb into LNP, unbound GrAb was removed after Amicon filtering, and the Cy5 fluorescence in the remaining protein was quantified and analyzed. An attachment rate of approximately 90% of the Grab antibody was confirmed at a mass ratio of 1:1.
[0178]
[0179] 4. Evaluation of DecLNP Intake Efficiency into Tumor Cells and DCs
[0180] To evaluate the intracellular uptake of DecLNP, flow cytometry and fluorescence microscopy were performed.
[0181] We confirmed that the selective uptake of DecLNP was increased in cells expressing DEC-205 (DCs and tumor cells). In cells not expressing DEC-205 (RAW264.7 macrophages), we observed that the uptake of DecLNP was limited. This suggests that DEC-205-mediated targeting was successfully achieved.
[0182] Meanwhile, in a receptor blocking assay, it was confirmed that pretreatment with an anti-DEC-205 antibody reduced the intracellular influx of DecLNP. This validates the specific delivery of DecLNP through the DEC-205 receptor.
[0183] Figure 6 shows the results of DEC-205-mediated endocytosis by DecLNP (analysis in cancer cells), analyzing the expression of DEC-205 and the induction of endocytosis by DecLNP (DEC-205 target LNP) in MC38 cells. The histogram on the left shows the results of measuring DEC-205 expression in MC38 cells treated with ConLNPs (Control LNPs) or DecLNPs (DEC-205 target LNPs) via flow cytometry. The graph on the right shows the results of quantifying and comparing the Mean Fluorescence Intensity (MFI) of DEC-205 after treatment with ConLNPs or DecLNPs at concentrations of 0–4.0 μg / mL. It was confirmed that significant changes in DEC-205 expression and the process of endocytosis occurred in MC38 cells as the concentration of DecLNP treatment increased. The expression level of extracellular DEC-205 decreased with DecLNP, which implies that DEC-205 is an endocytosis receptor and that surface DEC-205 is endocytized and consumed upon treatment with DecLNP.
[0184] Figure 7 shows the results of DEC-205-mediated endocytosis by DecLNP (analysis in dendritic cells), analyzing the expression of DEC-205 and the induction of endocytosis by DecLNP (DEC-205 target LNP) in MutuDC1940 cells. The histogram on the left shows the results of measuring DEC-205 expression in MutuDC1940 cells treated with ConLNPs (Control LNPs) or DecLNPs (DEC-205 target LNPs) via flow cytometry. The graph on the right shows the results of quantifying and comparing the mean fluorescence intensity (MFI) of DEC-205 after treatment with ConLNPs or DecLNPs at concentrations of 0–4.0 μg / mL. It was confirmed that changes in DEC-205 expression and the process of endocytosis in MutuDC1940 cells significantly increased with increasing DecLNP treatment concentration. DecLNP reduced the expression level of extracellular DEC-205, which implies that DEC-205 is an endocytosis receptor and that surface DEC-205 is endocytized and consumed upon treatment with DecLNP.
[0185] Meanwhile, Figure 8 shows the results of the recycling analysis of DEC-205 after DecLNP treatment. Changes in DEC-205 expression in MC38 (cancer cells) and MutuDC1940 (dendritic cells) were analyzed over time after treatment with DEC-205-targeted LNP (DecLNP). (A) shows a representative histogram (left) and the results of quantitative analysis of Mean Fluorescence Intensity (MFI) measured by flow cytometry at various time points after DecLNP treatment in MC38 cells and (B) MutuDC1940 cells. As time progressed after DecLNP treatment, a pattern was observed in which DEC-205 expression initially decreased but subsequently recovered during the recycling process. This suggests that DEC-205 undergoes temporary endocytosis after binding with DecLNP, but is redistributed to the cell membrane over time.
[0186] Meanwhile, Figure 9 shows the results of the analysis of intracellular influx of DEC-205-mediated GrAb-LNPs. To confirm the intracellular influx of GrAb-LNPs targeting DEC-205, the fluorescence intensity of DiD fluorescently labeled LNPs was evaluated by flow cytometry. In (A), DiD fluorescence signals were measured in DEC-205-expressing cells after treatment with ConLNPs (control LNPs without GrAb), IsoLNPs (IsoLNPs are GrAbs that do not bind to DEC-205, differing only from DecLNPs in the variable site targeting the antigen), and DecLNPs. As a result, significantly higher fluorescence intensity was confirmed in the DecLNPs-treated group. In (B), the same analysis was performed on DEC-205-non-expressing RAW264.7 cells, and the fluorescence intensity did not increase in the DecLNPs-treated group. Through this, it was confirmed that the intracellular influx of GrAb-LNPs is regulated by a DEC-205-mediated mechanism.
[0187] Meanwhile, Figure 10 shows the results of experiments on the intracellular influx and receptor blockade of DEC-205-mediated GrAb-LNPs. Changes in intracellular influx of GrAb-LNPs were analyzed after blocking the receptor using an anti-DEC-205 antibody. (A) shows the results of flow cytometry measurements of DiD fluorescence signals in groups with and without receptor blockade using the anti-DEC-205 antibody, after treating DEC-205-expressing cells with ConLNPs, IsoLNPs, and DecLNPs. (B) shows the results of quantifying and comparing the Mean Fluorescence Intensity (MFI) of DiD in tumor cells and dendritic cells expressing DEC-205 after pre-blocking with the anti-DEC-205 antibody. In the group that blocked the receptor with antibodies, a decrease in DiD fluorescence intensity was observed even after treatment with DecLNPs, suggesting that the intracellular influx of GrAb-LNPs is regulated by a DEC-205-mediated mechanism.
[0188]
[0189] 5. Evaluation of DecLNP mRNA delivery and expression efficiency
[0190] To evaluate the antigen expression efficiency of mRNA@DecLNP, expression was measured using Cy5-labeled mRNA and mFLuc (mRNA-encoding Firefly Luciferase). Treatment of DCs and tumor cells expressing DEC-205 with DecLNP confirmed a significant increase in mRNA influx and expression. In in vivo experiments, the highest mRNA expression was observed in the tumors and lymph nodes of the DecLNP-treated group. Furthermore, non-specific liver accumulation was reduced compared to conventional LNP, leading to increased selective delivery to tumors and lymph nodes.
[0191] Figure 11 shows the results of the analysis of DEC-205-mediated mRNA intracellular uptake and expression. To determine whether DEC-205-targeted LNPs (DecLNPs) effectively induce the intracellular uptake and expression of mRNA in tumor cells and dendritic cells (DCs), the intracellular delivery efficiency of LNPs loaded with Cy5 and mFLuc (mRNA-encoding Firefly Luciferase) was analyzed. In (A), the mRNA distribution in tumor cells and DCs was analyzed by confocal microscopy after treatment with ConLNPs (Control LNPs), IsoLNPs (Isotype control LNPs), and DecLNPs (DEC-205-targeted LNPs) loaded with Cy5-labeled mRNA. Cy5 signaling was significantly increased in the group treated with DecLNPs, indicating that mRNA delivery was effectively achieved via a DEC-205-mediated mechanism. The scale bar is 100 μm. In (B), intracellular mRNA influx was quantitatively analyzed using Cy5 fluorescence signals. When the Cy5-positive area of each group was normalized by the number of cells and compared, the highest mRNA delivery efficiency was confirmed in the group treated with DecLNPs. In (C), mRNA expression levels were evaluated by measuring luminescence intensity in tumor cells and DCs after treatment with ConLNPs, IsoLNPs, and DecLNPs loaded with mFLuc (mRNA-encoding Firefly Luciferase). The highest luminescence signal was observed in the DecLNPs-treated group, suggesting that DEC-205-mediated LNPs effectively induce mRNA expression. These results imply that LNPs targeting DEC-205 effectively increase intracellular mRNA influx and expression, and can be utilized as a platform to maximize antigen expression in tumor cells and dendritic cells.
[0192] Figure 12 shows the results of confirming the selective mRNA delivery into tumors and lymph nodes using dual-targeting LNPs (DecLNP) (C57BL / 6 mouse model). To determine whether dual-targeting LNPs (DecLNP) targeting DEC-205 can selectively deliver mRNA to tumors and lymph nodes (TDLNs) in vivo, IVIS imaging and tissue analysis were performed in MC38 xenograft mice. In (A), ConLNPs (Control LNPs), IsoLNPs (Isotype control LNPs), and DecLNPs (DEC-205 targeting LNPs) loaded with mFLuc (mRNA-encoding Firefly Luciferase) were intravenously injected into C57BL / 6 mice, and mRNA expression within the tumor was visualized via IVIS (In Vivo Imaging System) imaging. In mice injected with DecLNPs, the luminescence signal was strongest at the tumor site, indicating that selective mRNA delivery within the tumor was enhanced by DEC-205 targeting. In (B), the average radiance efficiency at the tumor site was quantified and compared over time using IVIS analysis. In the DecLNPs group, consistently high luminescence signals were maintained over time, suggesting that mRNA delivery and expression within the tumor were effectively achieved. In (C), ex-vivofluorescence images of excised tumors and lymph nodes (TDLNs) were acquired 24 hours after administration. Strong fluorescence signals were observed in the tumors and TDLNs of the DecLNPs treatment group, indicating that the DEC-205 targeting strategy increased selective delivery to the lymph nodes. In (D), the average radiance efficiency of the collected tumors and TDLNs was quantified and compared.The luminescence intensity in tumors and lymph nodes was highest in the DecLNPs group, suggesting that it can be utilized as an effective antigen delivery strategy to induce tumor-specific immune responses. In (E), tumor and lymph node tissues were analyzed using Histological Fluorescence Imaging to confirm the distribution of mRNA delivery within the tissues after treatment with DecLNPs. Strong fluorescent signals were observed within the tumors and lymph nodes in the DecLNPs-treated group, with a scale bar of 500 μm. These results demonstrate that dual-targeting LNPs (DecLNPs) targeting DEC-205 can selectively deliver mRNA to tumors and lymph nodes in vivo, implying that they can be utilized as an effective anticancer vaccine platform.
[0193] In addition, Figure 13 shows the results confirming selective mRNA delivery within tumors and lymph nodes using dual-targeting LNPs in a BALB / c mouse model. To verify whether dual-targeting LNPs (DecLNPs) targeting DEC-205 effectively deliver mRNA to tumors and lymph nodes (TDLNs) in a BALB / c mouse model, fluorescence imaging and tissue analysis were performed. In (A), after intravenously injecting DecLNPs loaded with mRNA, the in vivo distribution of mRNA was confirmed via whole-body fluorescence imaging. In the DecLNPs-treated group, a pattern of fluorescence signal concentration in the tumor site was observed, indicating enhanced tumor-specific mRNA delivery. In (B), changes in the fluorescence signal in the tumor site over time were compared to evaluate how long the mRNA was continuously expressed within the tumor. In the DecLNPs-treated group, a high fluorescence signal was maintained over time, suggesting continuous mRNA delivery and expression within the tumor. In (C), ex-vivo fluorescence imaging and histological fluorescence imaging were performed on tumors and lymph nodes (TDLNs) excised 24 hours after administration. Strong fluorescence signals were observed within the tumors and lymph nodes in the DecLNPs-treated group, indicating that the DEC-205 targeting strategy promotes selective delivery to both tumors and lymph nodes. The scale bar is 200 μm. In (D), the intratumoral luminescence intensity normalized based on the luminescence signal in the liver was quantified to evaluate whether DecLNPs improve the selective intratumoral delivery efficiency compared to conventional LNPs. The relative tumor fluorescence signal in the liver significantly increased in the DecLNPs group, demonstrating that it is effective in enhancing intratumoral antigen delivery while reducing non-specific liver accumulation.These results indicate that a dual-targeting LNP (DecLNP) targeting DEC-205 successfully induces selective mRNA delivery to tumors and lymph nodes in BALB / c mouse models and can be utilized as an anticancer vaccine platform capable of maximizing the immune response.
[0194] Meanwhile, Figure 14 shows the results of an in vivo analysis of DEC-205-mediated mRNA translation efficiency. After administering dual-targeting LNPs (DecLNPs) targeting DEC-205, an analysis based on luminescence signals was performed to evaluate the translation efficiency of mRNA in tumors and lymph nodes (TDLNs). In (A), ex-vivoluminescence images of excised tumors and lymph nodes were acquired 24 hours after intravenous injection of DecLNPs. Strong luminescence signals were observed in the tumors and lymph nodes of the DecLNPs-treated group, indicating that mRNA was effectively delivered and transcribed. In (B), ex-vivoluminescence images of major organs (liver (Li), kidney (Ki), spleen (Sp), lung (Lu), heart (He)) were acquired 24 hours after administration to evaluate the in vivo distribution of DecLNPs. In the DecLNPs-treated group, signals in the liver and lungs were relatively low, indicating a reduction in non-specific liver accumulation compared to conventional LNPs. In (C), luminescence intensity was normalized to organ weight to quantitatively compare the in vivo distribution and translation efficiency of mRNA. In the DecLNPs-treated group, luminescence intensity was highest in tumors and lymph nodes, while low signals were observed in other organs, including the liver. These results suggest that dual-targeting LNPs (DecLNPs) utilizing the DEC-205 targeting strategy can selectively deliver mRNA to tumors and lymph nodes and induce effective antigen expression. This confirms that the drug can serve as a platform to resolve the issue of non-specific liver accumulation associated with existing mRNA vaccines and to maximize anti-cancer immune responses.
[0195] Figure 15 shows the results of confirming the optimization of the CpG ratio in the mRNA@LNP formulation. In this experiment, 'CpG' refers to a 'CpG agonist,' which is a substance containing a CpG nucleotide sequence that stimulates TLR9. In this invention, a CpG agonist having the sequence (5'-tccatgacgttcctgacgtt-3') of SEQ ID NO. 5 was used. The mRNA encapsulation efficiency and the degree of dendritic cell (DC) activation were evaluated by adjusting the ratio of the CpG agonist in dual-targeting LNPs (DecLNPs) targeting DEC-205. In (A), the mRNA encapsulation efficiency of DecLNPs was analyzed at different mRNA:CpG ratios. It was confirmed that mRNA is effectively loaded into LNPs when an appropriate CpG ratio is maintained. In (B), the effect of the CpG ratio on the physical properties of DecLNPs was analyzed by measuring the Z-average size and Polydispersity Index (PDI) of DecLNPs using Dynamic Light Scattering (DLS). Above a certain ratio, an increase in particle size and a change in PDI values were observed, indicating the possibility of reduced particle stability with excessive CpG addition. In (C), changes in CD40 expression on the surface of MutuDC1940 cells were evaluated via flow cytometry after treating them with DecLNPs. CD40 is a marker associated with DC activation and antigen presentation functions, and CD40 expression tended to increase when the CpG ratio was optimized. In (D), the degree of DC activation according to CpG content was analyzed by measuring the Mean Fluorescence Intensity (MFI) of CD86. CD86 is a co-stimulator of DCs, and high expression is associated with T cell activation. CD86 expression was highest at a specific CpG ratio, suggesting that optimal CpG concentration plays an important role in DC activation and immune response enhancement.These results indicate that regulating the CpG ratio in mRNA@LNP formulations has a significant impact on mRNA encapsulation efficiency and DC activation, and that an appropriate CpG:mRNA ratio is required to optimize the immune response.
[0196] Figure 16 shows the results of CpG ratio optimization and immune response analysis in mRNA@LNP formulations. The effects of the CpG ratio on mRNA delivery within lymph nodes, dendritic cell (DC) activation, and antigen presentation efficiency in dual-targeting LNPs (DecLNPs) targeting DEC-205 were evaluated. In (A), mRNA delivery efficiency was evaluated by acquiring ex-vivoluminescence images of lymph nodes (TDLNs, Tumor-Draining Lymph Nodes) extracted 24 hours after injecting DecLNPs prepared with different mRNA:CpG ratios. The strongest luminescence signal was observed in the group with the optimized CpG ratio, suggesting that CpG can enhance mRNA delivery and expression within lymph nodes. In (B), the average radiance efficiency of the collected TDLNs was quantified to compare differences in mRNA expression according to CpG concentration. At a specific CpG ratio, the luminescence intensity significantly increased, while a decreasing trend was observed at excessive CpG content. In (C) and (D), CD40 in TDLNs was analyzed via flow cytometry. + and CD86 +The effect of CpG concentration on DC activation was evaluated by quantifying the ratio of DCs. CD40 and CD86 expression were highest at the optimal CpG ratio, indicating that the addition of appropriate CpG contributes to DC activation and the enhancement of antigen presentation function. (E) presents a representative histogram of H-2K-OVAp complex (H-2K-OVA peptide complex) expression measured by flow cytometry in MutuDC1940 cells. The H-2K-OVAp complex is an indicator of antigen presentation via MHC-I, and its expression was highest at a specific CpG ratio. (F) analyzes the effect of CpG ratio on DC antigen presentation efficiency through a graph quantifying H-2K-OVAp complex expression. Antigen presentation via MHC-I was most effective at the optimal CpG ratio, suggesting that it may play an important role in enhancing DC-based immune responses. These results demonstrate that optimizing the CpG ratio in mRNA@LNP vaccine formulations can enhance mRNA delivery and expression within lymph nodes, and maximize the activation and antigen presentation functions of DCs. Consequently, it was assessed that this formulation has sufficient potential to be utilized as an effective anticancer vaccine platform that optimizes the immune response.
[0197]
[0198] 6. Evaluation of Antigen Presentation Efficiency and Immune Response of DecLNP
[0199] To evaluate antigen-specific immune responses, antigen presentation via MHC-I (H-2K b -OVA complex) and CD8 + T cell activation analysis was performed. It was confirmed that antigen presentation via MHC-I in DCs and tumor cells increased in the DecLNP-treated group. In addition, as a result of evaluating antigen-specific OT-1 T cell responses, IFNγ + and CD44 + CD8 +The proportion of T cells was highest in the DecLNP-treated group. In addition, in co-culture experiments, DC and tumor cells treated with DecLNP were shown to effectively activate OT-1 T cells.
[0200] Fig. 17 is mOVA CPG This is the result of an antigen presentation activation analysis (in vitro) using @DecLNPs. A dual-targeting LNP (DecLNP) targeting DEC-205 contained mRNA (mOVA) encoding a CpG agonist (SEQ No. 5) and the OVA antigen (SEQ No. 6). CPG The MHC-I mediated antigen presentation efficiency in tumor cells (MC38) and dendritic cells (MutuDC1940) was evaluated by loading mOVA. In (A), MC38 cells were loaded with mOVA CPG This shows the results of measuring H-2K-OVAp peptide complex expression by flow cytometry after treatment with @DecLNPs. H-2K-OVAp expression was significantly increased in the DecLNPs-treated group compared to the control group, indicating that mRNA delivered into tumor cells was effectively translated and antigens were presented via MHC-I. In (B), the same experiment was performed on MutuDC1940 cells to evaluate whether antigen presentation activation occurred in dendritic cells as well. H-2K-OVAp complex expression showed a significant increase in the DecLNPs-treated group, suggesting that the antigen presentation function of DCs is enhanced through mRNA delivery and CpG immune supportive effects. These results demonstrate that a dual-targeting mRNA vaccine targeting DEC-205 can effectively express antigens in tumor cells and DCs, promote antigen presentation via MHC-I, and induce a potent CD8 T cell response.
[0201] Meanwhile, Fig. 18 is a schematic diagram of a co-culture analysis experiment. To evaluate whether isolated OT-1 T cells are more effectively activated in the DEC-205-targeted dual-targeting LNP (DecLNP) treatment group, a schematic diagram of an experiment analyzing antigen-specific immune responses by co-culturing OT-1 T cells with MutuDC1940 (dendritic cells) or MC38 (tumor cells) is presented. In the experiment, MutuDC1940 or MC38 cells were treated with mOVA CpG @ConLNPs(Control LNPs) or mOVA CpG After treatment with @DecLNPs (DEC-205 targeted LNPs), the immune response was evaluated by co-culture with antigen-specific OT-1 T cells. Through this experiment, we were able to analyze the effect of the DEC-205 targeting strategy on OT-1 T cell activation and immune response enhancement by increasing antigen presentation in DCs and tumor cells.
[0202] Figure 19 shows the results of the antigen-mediated OT-1 T cell activation analysis. To evaluate whether dual-targeting LNP (DecLNP) targeting DEC-205 effectively induces antigen-specific T cell responses, OT-1 T cells were co-cultured with dendritic cells (MutuDC1940) or tumor cells (MC38), and T cell activation indicators were analyzed via flow cytometry. In (A) and (B), CD3 + CD8 + Representative flow cytometry dot plots and quantified graphs measuring interferon gamma (IFNγ) expression in OT-1 T cells are presented. IFNγ expression was significantly increased in the DecLNPs-treated group, indicating that antigen-specific T cell responses were effectively induced. In (C) and (D), the expression ratios of the proliferation marker Ki67 and the activation marker CD44 in OT-1 T cells were analyzed. Ki67 in the DecLNPs-treated group +and CD44 + A high proportion of T cells was observed, suggesting enhanced T cell proliferation and activation. In (D), the proportion of CD44-expressing cells and the Mean Fluorescence Intensity (MFI) were compared among OT-1 T cells. CD44 expression increased in the DecLNPs-treated group, indicating that the T cells reached a high level of activation. These results suggest that the dual-targeting mRNA vaccine targeting DEC-205 is an antigen-specific CD8 + It demonstrates that it can effectively induce a T cell response and has high potential for use as an immunotherapy.
[0203]
[0204] 7. Analysis of Antitumor Effects and In Vivo Immune Response of DecLNP
[0205] The antitumor effects of DecLNP were evaluated in MC38 and 4T1-Luc tumor models. IVIS imaging confirmed that DecLNP is selectively delivered to tumors and lymph nodes. In addition, in vivo CD8 + It was confirmed that T cell responses increased and tumor invasion significantly increased. In addition, cytotoxic T cell (CTL) analysis revealed that GrzB (Granzyme B) expression increased in the DecLNP-treated group, and the tumor cell killing effect significantly increased. Furthermore, survival analysis confirmed that the survival rate in the DecLNP-treated group was significantly higher compared to the control group.
[0206] Figure 20 shows the results of antigen-specific tumor cell killing analysis. Dual-targeting LNP (DecLNP) targeting DEC-205 antigen-specific CD8 +To evaluate whether T cells (OT-1 T cells) are effectively killed by activation, GrzB (Granzyme B) expression, T cell-tumor cell interactions, and cytotoxic T cell (CTL) analysis were performed. (A) and (B) present flow cytometry dot plots and quantified graphs measuring the expression of the cytotoxic factor Granzyme B (GrzB) in OT-1 T cells. GrzB expression was significantly increased in the DecLNPs-treated group, indicating that antigen-specific cytotoxic T cell (CTL) responses were effectively induced. (C) analyzes how T cells bind to MC38 tumor cells using optical microscopy images. PBS, mOVA CpG MC38 tumor cells treated with @ConLNPs (Control LNPs) and DecLNPs (DEC-205 targeted LNPs) were co-cultured with OT-1 T cells (E:T ratio = 10:1), and the interactions between T cells and tumor cells were observed. Increased close binding between T cells and tumor cells was confirmed in the DecLNPs-treated group, suggesting that DecLNPs effectively promote T cells' recognition of tumor cells. In (D), MC38 tumor cells labeled with Far Red fluorescence were co-cultured with OT-1 T cells, and the tumor cell killing rate was evaluated by performing a CTL (cytotoxic T cell) assay. CTL activation significantly increased in the DecLNPs-treated group, indicating improved efficiency in antigen-specific tumor cell elimination. These results suggest that the dual-targeting mRNA vaccine targeting DEC-205 is an antigen-specific CD8 + It demonstrates that it can induce a T cell response and effectively eliminate tumor cells through activated cytotoxic T cells (CTLs).
[0207] Meanwhile, Fig. 21 shows an in vivo OVA-specific CD8+ These are the results of the T cell induction and CTL activation analysis. Dual-targeting LNP (DecLNP) targeting DEC-205 OVA-specific CD8 in vivo + We evaluated whether T cell responses could be induced and tumor cells eliminated via activated cytotoxic T cells (CTLs). (A) shows the experimental schedule for in vivo OVA-specific CD8 T cell induction and analysis of Ex VivoCTL (cytotoxic T cell) activity. After administering ConLNPs (Control LNPs), IsoLNPs (Isotype control LNPs), or DecLNPs (DEC-205 target LNPs) to mice, CD8 T cells were isolated at specific time points and CTL activity was evaluated. (B) shows CD8 + Optical microscopy was used to analyze how T cells interact with MC38 tumor cells expressing OVA. In the DecLNPs-treated group, CD8 + An increase in close binding between T cells and tumor cells was observed, suggesting that DecLNPs effectively induced antigen-specific T cell responses. In (C), CD8 cells isolated from each LNP-treated mouse + CTL activity was evaluated by co-cultured T cells with Far Red fluorescently labeled OVA-expressing MC38 tumor cells. The highest tumor cell killing rate was observed in the DecLNPs-treated group, which is due to the fact that DecLNPs in vivo [act on] OVA-specific CD8 + This implies that it effectively activated T cells and increased T cell-mediated tumor-eliminating ability. These results indicate that DEC-205-targeted dual-targeting mRNA vaccines (DecLNPs) in vivo OVA-specific CD8 + It demonstrates that it can induce a T cell response and thereby elicit a powerful anti-cancer immune response.
[0208] Fig. 22 is a dual-targeting mOVA CpG This is the result of the analysis of the potent antitumor effects of @DecLNPs. To evaluate whether dual-targeting LNPs (DecLNPs) targeting DEC-205 induce an anti-cancer immune response in vivo and effectively inhibit tumor growth, the antitumor effects were analyzed in an MC38 tumor-grafted mouse model. (A) shows the experimental design for evaluating in vivo anti-cancer efficacy. Mice grafted with MC38 tumors were administered ConLNPs (Control LNPs), IsoLNPs (Isotype control LNPs), or DecLNPs (DEC-205 targeted LNPs) at a dose of 0.75 mg / kg, after which tumor growth and treatment response were evaluated. (B) presents the average tumor growth curves obtained by measuring changes in tumor size in each LNP treatment group. The DecLNPs treatment group showed a significant decrease in tumor size over time, indicating that the dual-targeting strategy can induce a potent antitumor response. In (C), images of tumors excised after the experiment were compared to visually confirm that the tumor size in the DecLNPs-treated group was significantly reduced compared to the control group. In (D), the weight of the excised tumors was quantitatively compared, indicating that the lowest tumor weight was measured in the DecLNPs-treated group. These results demonstrate that the DEC-205-targeted dual-targeting mRNA vaccine (DecLNPs) induces a potent anti-cancer immune response and can effectively inhibit tumor growth in vivo.
[0209] Figure 23 shows the results of the analysis of the immune response within the tumor tissue. To evaluate the anticancer immune response of the dual-targeting LNP (DecLNP) targeting DEC-205, the composition and activation status of immune cells in MC38 tumor tissue were analyzed using flow cytometry. In (A), the proportion of various immune cells within the MC38 tumor tissue on day 21 was analyzed to evaluate the effect of the DEC-205-targeted vaccine on the intratumoral immune environment. CD8 in the DecLNPs-treated group + An increasing trend in the proportion of T cells, dendritic cells (DCs), and macrophages was confirmed. This suggests that DecLNPs can promote anti-cancer immune responses by regulating the immune microenvironment within the tumor. In (B), CD45 in MC38 tumor tissue + CD11c + The effect of DecLNPs on DC activation was analyzed by quantifying the expression ratios of CD40 and CD86 in dendritic cells (DCs). In the DecLNPs-treated group, CD40 + and CD86 + The proportion of DCs significantly increased, indicating that the antigen-presenting function of DCs was enhanced and T-cell activation ability was improved. These results demonstrate that DEC-205-targeted dual-targeting mRNA vaccines (DecLNPs) can induce an effective anti-cancer immune response by reconstructing the immune environment within tumor tissues.
[0210] Figure 24 shows the results of conglomerate image analysis for the analysis of CD8 / IFNγ killer T cells in tumor tissue. Dual-targeting LNP (DecLNP) targeting DEC-205 CD8 in tumor tissue + To evaluate the effects on T cell infiltration and activation, confocal microscopy images using immunofluorescence staining were acquired. CD8 +Immunofluorescence analysis was performed on T cells (CD8, bright area) and activated interferon gamma (IFNγ)-expressing cells (bright area) in the whole tumor. In mice treated with DecLNPs, CD8 + It was confirmed that T cell infiltration into the tumor increased and IFNγ expression was enhanced. The scale bar is 1 mm, suggesting that the DEC-205-targeted dual-targeting vaccine can induce T cell infiltration into the tumor and promote an activated cytotoxic immune response.
[0211] Figure 25 shows the results of the immune response analysis in tumor-draining lymph nodes (TDLNs) and the spleen. The effects of a dual-targeting LNP (DecLNP) targeting DEC-205 on the activation of DCs and memory T cells in tumor-draining lymph nodes (TDLNs) and the spleen were evaluated by flow cytometry. In (A), CD45 in TDLNs + CD11c + The effect of DecLNPs on DC activation was analyzed by quantifying the expression ratios of the activation markers CD40 and CD86 in dendritic cells (DCs). In the DecLNPs-treated group, CD40 + and CD86 + The proportion of DCs significantly increased, suggesting that DecLNPs can induce an effective immune response by promoting DC maturation and enhancing antigen presentation function. In (B), effector memory T cells (CD44) in the spleen high CD62L lowThe effect of DecLNPs on the formation of long-term immune memory was evaluated by analyzing the ratio of ). The ratio of effector memory T cells significantly increased in the DecLNPs-treated group, which implies that the vaccine can induce a potent antigen-specific immune memory response. These results demonstrate that the DEC-205-targeted dual-targeting mRNA vaccine (DecLNPs) has high potential to be utilized as a potent vaccine platform capable of promoting DC activation in lymph nodes and forming long-term immune memory in the spleen.
[0212]
[0213] 8. Biosafety Assessment of DecLNP
[0214] To evaluate the in vivo safety of DecLNP, body weight change monitoring, blood chemistry analysis (ALT, AST, BUN, Creatinine), and tissue analysis were performed. Body weight change in the DecLNP-treated group remained similar to that of the control group. In addition, hepatic and renal toxicity indicators (ALT, AST, BUN, Creatinine) remained within the normal range. Furthermore, tissue analysis confirmed that there was no significant increase in toxicity in major organs (liver, kidney, heart, lungs, spleen).
[0215] Fig. 26 is an mOVA CpGAs a result of evaluating in vivo safety after administration of @DecLNPs, liver and kidney toxicity indicators were analyzed through body weight changes and blood chemistry analysis to assess the in vivo safety of dual-targeting LNPs (DecLNPs) targeting DEC-205. In (A), body weight changes in mice were monitored in each LNP treatment group to evaluate whether DecLNPs induce systemic toxicity. Body weight changes in the DecLNPs treatment groups remained similar to those of the control group, indicating that DecLNPs did not induce body weight loss and overall in vivo safety was maintained. In (B), liver enzyme levels (ALT, AST) were measured to evaluate liver toxicity through blood chemistry analysis. ALT and AST levels in the DecLNPs treatment groups remained within the normal range, indicating that liver toxicity did not significantly increase. In (C), blood creatinine and BUN (Blood Urea Nitrogen) levels were measured to evaluate kidney toxicity. Creatinine and BUN levels in the DecLNPs-treated group remained similar to those of the control group, indicating that renal function was maintained normally. These results demonstrate that the DEC-205-targeted dual-targeting mRNA vaccine (DecLNPs) exhibits excellent in vivo safety and has high potential to be utilized as an effective vaccine platform that does not induce hepato-renal toxicity.
[0216] Meanwhile, Figure 27 shows the results of the evaluation of the antitumor efficacy of the low-dose dual-targeting vaccine. To evaluate the antitumor effect and in vivo safety of a low dose (0.4 mg / kg) of a dual-targeting LNP (DecLNP) targeting DEC-205, in vivo experiments were performed in a 4T1-Luc tumor-grafted mouse model. (A) presents the experimental design using an orthotopic 4T1-Luc breast cancer tumor model. Tumor growth and immune response were evaluated after intravenously injecting ConLNPs (Control LNPs), IsoLNPs (Isotype control LNPs), or DecLNPs (DEC-205-targeted LNPs) at a dose of 0.4 mg / kg. (B) ALT (Alanine Aminotransferase) and AST (Aspartate Aminotransferase) levels were measured via blood chemistry analysis to evaluate hepatotoxicity. Liver enzyme levels in the DecLNPs treatment group remained similar to those of the control group, suggesting that hepatotoxicity did not significantly increase with low-dose vaccine administration. In (C), blood creatinine and BUN (Blood Urea Nitrogen) levels were analyzed to evaluate renal toxicity. Creatinine and BUN levels in the DecLNPs treatment group remained within the normal range, indicating that the low-dose vaccine did not affect renal function. These results demonstrate that the DEC-205-targeted dual-targeting mRNA vaccine (DecLNPs) can be utilized as a safe vaccine platform that maintains antitumor effects even at low doses without inducing hepatotoxicity or renal toxicity.
[0217] Figure 28 shows the results of the analysis of the antitumor efficacy of the low-dose dual-targeting vaccine. To evaluate whether the dual-targeting LNP (DecLNP) targeting DEC-205 can maintain an antitumor effect even at a low dose (0.4 mg / kg), tumor growth inhibition and immune response were analyzed in a 4T1-Luc tumor-grafted mouse model. In (A), bioluminescence imaging was performed in an orthotopic 4T1-Luc tumor model to evaluate changes in tumor growth after treatment with ConLNPs (Control LNPs), IsoLNPs (Isotype control LNPs), or DecLNPs (DEC-205-targeted LNPs). In the DecLNPs treatment group, the luminescence signal at the tumor site showed a decreasing trend over time, suggesting that DecLNPs can exhibit a potent anticancer effect even at low doses. In (B), the average tumor growth curves were compared by measuring the tumor size in each treatment group. The tumor growth rate was significantly reduced in the DecLNPs-treated group, indicating that the tumor-suppressing effect was maintained. In (C), survival rates were analyzed in each treatment group to evaluate the effect of DecLNPs on extending survival time. The highest survival rate was maintained in the DecLNPs-treated group, suggesting that the anti-cancer immune response can be sustained even at low doses. In (D), CD8 T cell and IFNγ expression in tumor tissue were evaluated using immunofluorescence imaging. In the DecLNPs-treated group, CD8 +Increased T cell infiltration and a significant increase in IFNγ expression were observed. This suggests that DecLNPs can effectively induce cytotoxic T cell responses within tumors even at low doses. The scale bar is 200 μm. These results demonstrate that DEC-205-targeted dual-targeting mRNA vaccines (DecLNPs) can be utilized as an effective anticancer vaccine platform capable of inhibiting tumor growth, increasing survival rates, and inducing potent immune responses even at low doses.
[0218]
[0219] The DEC-205-targeted dual-targeting mRNA vaccine (DecLNP) developed through this invention can maximize antigen-specific immune responses by co-expressing antigens in DCs and tumor cells, and provides a new platform capable of resolving the problem of intratumoral antigen deficiency inherent in existing vaccines. DecLNP exhibits potent CD8 in vivo + By inducing T cell responses and effectively inhibiting tumor growth while maintaining high biocompatibility, it has high potential to be utilized as a next-generation anticancer vaccine.
[0220]
[0221] [Example 2: Evaluation of Cell Binding and mRNA Delivery Efficiency of Lipid Nanoparticles According to Helper Lipid Composition]
[0222] I. Experimental Objective
[0223] In this example, we aimed to compare the cell binding and mRNA delivery efficiency of lipid nanoparticles according to the helper lipid composition.
[0224]
[0225] II. Experimental Method
[0226] In this example, lipid nanoparticles containing DSPC and DOPE as helper lipids were prepared to evaluate the effect of changes in the helper lipid composition of lipid nanoparticles on the delivery efficiency to immune cells. The lipid nanoparticles were prepared by composing SM-102:helper lipid:cholesterol:PEG lipid in a molar ratio of 50:10:38.5:1.5 (for other technical details regarding the preparation of lipid nanoparticles, refer to Example 1). Each lipid nanoparticle was compared with DecLNPs having antibodies attached to their surface for DC targeting and a control group (ConLNP) without attached antibodies.
[0227] To explain in more detail, it was as follows. Lipid nanoparticles were prepared by composing SM-102:helper lipid:cholesterol:PEG lipid in a molar ratio of 50:10:38.5:1.5. Some of the prepared lipid nanoparticles had antibodies attached to their surfaces to form DC-targeted lipid nanoparticles (DecLNP), and lipid nanoparticles without attached antibodies were used as a control group (ConLNP).
[0228] For cell binding analysis, MutuDC1940 cells and HepG2 cells were each 1×10 6 After preparing the cells, fluorescently labeled lipid nanoparticles were added and reacted for 2 hours. Subsequently, the cells were washed to remove non-specific binding, and intracellular fluorescence signals were measured using a flow cytometer, and the mean fluorescence intensity (MFI) was quantified.
[0229] The mRNA delivery efficiency was evaluated by treating cells with lipid nanoparticles containing 40 ng of Cy5-labeled mRNA under the same conditions and culturing them for 24 hours. Afterward, the cells were collected and washed, and the Cy5 fluorescence signal was measured using a flow cytometer to quantitatively analyze intracellular mRNA uptake based on this.
[0230] Through the above method, cell binding and mRNA delivery efficiencies were compared and evaluated according to helper lipid composition and antibody attachment.
[0231]
[0232] III. Experimental Results
[0233] The experimental results are shown in Figure 29. Cell binding and mRNA delivery efficiency were evaluated using MutuDC1940 cells as an immune cell model. As a result, antibody-attached DecLNP exhibited higher cell binding rates and mRNA uptake compared to antibody-unattached ConLNP in both DSPC and DOPE compositions. In particular, the cell binding and mRNA delivery efficiency of DecLNP were found to be further enhanced compared to the DSPC composition in lipid nanoparticles containing DOPE as a helper lipid.
[0234] Meanwhile, in non-target HepG2 cells, no increase in cell binding following antibody attachment was observed, confirming that this system possesses selective binding and delivery characteristics for DCs.
[0235] From these results, it was confirmed that antibody-based targeting strategies effectively enhance DC-specific binding and mRNA delivery efficiency under various lipid composition conditions, and in particular, compositions containing DOPE exhibit superior delivery efficiency compared to DSPC.
Claims
1. A pharmaceutical composition for the prevention or treatment of cancer in which a DEC-205 receptor is expressed on the surface of cancer cells, comprising a ‘DEC-205 bound lipid nanoparticle’ having an antibody or antibody fragment capable of binding to both a DEC-205 receptor expressed on the surface of dendritic cells and a DEC-205 receptor expressed on the surface of cancer cells, and having mRNA loaded inside.
2. In Paragraph 1, The above 'antibody or antibody fragment capable of binding to both the DEC-205 receptor expressed on the surface of dendritic cells and the DEC-205 receptor expressed on the surface of cancer cells' is, A pharmaceutical composition characterized by being bonded to lipid nanoparticles through chemical bonding.
3. In Paragraph 2, The above chemical bond is, A maleimide-thiol reaction in which a maleimide functional group is introduced into the lipids of lipid nanoparticles, and then a chemical reaction is induced between the maleimide functional group and the thiol functional group of an antibody to form a chemical bond; An amine-carboxyl reaction that forms a chemical bond between the carboxyl group (-COOH) present in the lipids of lipid nanoparticles and the amine group (-NH2) of the antibody; Click chemistry (CuAAC, SPAAC) reaction in which azide (-N₃) or alkyne (-C≡C) functional groups are introduced into the lipids of lipid nanoparticles and click-reactive functional groups are introduced into antibodies, and then chemical bonds are formed through a click reaction between them; A hydrazine or oxime binding reaction in which an aldehyde functional group is introduced into lipid nanoparticle lipids, a hydrazine (-NH-NH₂) or oxime (-C=NOH) functional group is introduced into antibodies, and then a chemical reaction between them is induced to form a chemical bond; and A pharmaceutical composition characterized by being formed by any one of the following chemical reactions: a Staudinger ligation reaction in which a phosphine functional group is introduced to the lipids of lipid nanoparticles and an azide (N₃) functional group is introduced to the antibody, and then a chemical reaction is induced between them to form a chemical bond.
4. In Paragraph 1, The above 'antibody or antibody fragment capable of binding to both the DEC-205 receptor expressed on the surface of dendritic cells and the DEC-205 receptor expressed on the surface of cancer cells' is, A pharmaceutical composition characterized by binding an antibody or antibody fragment capable of binding to both the DEC-205 receptor expressed on the surface of dendritic cells and the DEC-205 receptor expressed on the surface of cancer cells, and then binding to the hydrophobic portion of the lipid constituting the shape of a lipid nanoparticle via hydrophobic binding through the membrane scaffold protein.
5. In Paragraph 1, The above mRNA is, A pharmaceutical composition characterized by being an mRNA anticancer vaccine.
6. In Paragraph 1, The above 'DEC-205 bound lipid nanoparticles' are, A pharmaceutical composition characterized by having a CpG agonist loaded inside.
7. In Paragraph 1, The above pharmaceutical composition is, A pharmaceutical composition characterized as being a vaccine.
